Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
Phase of Trial: Phase IV
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia; Post-traumatic stress disorders
- Focus Therapeutic Use
- 04 Sep 2019 Status changed from not yet recruiting to recruiting.
- 15 Aug 2019 Planned initiation date changed from 17 Jun 2019 to 30 Aug 2019.
- 29 May 2019 Planned initiation date changed from 15 Apr 2019 to 17 Jun 2019.